Targeting Reductive Metabolic Shifts by T315I Mutation in BCR-ABL Myeloid Leukemia for Therapy
C. Y. Huang, Y.-H. Chung, S.-Y. Wu, H.-Y. Wang, Z.-Y. Lin, T.-J. Yang, J.-M. Feng, C.-M. Hu, Z.-F. Chang
This study identifies metabolic shifts in T315I-Bcr-Abl CML and shows that combining JMF4073 with UK-5099 eradicates the disease in vivo.
bioRxiv · Mar 22, 2022 · PreprintCancer Biology